Български
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Страница 1 от 81 резултата
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
2. BACKGROUND
The connection between abnormal protein
Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound and an effective amount of an androgen receptor antagonist to a patient having a cancer.
2. BACKGROUND
The connection between abnormal protein
Treatment of cancer with dihydropyrazino-pyrazines
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia (CLL), or T-cell prolymphocytic leukemia (T-PLL).
2. BACKGROUND
The
Treatment of cancer with dihydropyrazino-pyrazines
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a patient having chronic lymphocytic leukemia (CLL), or T-cell prolymphocytic leukemia (T-PLL).
2. BACKGROUND
The
Treatment of cancer with dihydropyrazino-pyrazines
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O.sup.6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a
Treatment of cancer with dihydropyrazino-pyrazines
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing glioblastoma multiforme (GBM) characterized by O.sup.6-methylguanine-DNA methyltransferase (MGMT) expression and/or promoter methylation status, comprising administering an effective amount of a Dihydropyrazino-Pyrazine Compound to a
Substituted imidazo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines and oxazolo[4',5':4,5]cyclopenta[1,2-e]pyrrolo[1,2-a]pyrazines for treating brain cancer
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
TECHNICAL FIELD
This document relates to compounds and compositions useful for treating cancers, including brain and nervous system cancers.
BACKGROUND
Agelastatin A is an oroidin alkaloid extracted from an axinellid sponge, Agelas dendromorpha. It has anti-neoplastic activities against multiple
Substituted thieno[3,2-b]pyrazines for inhibiting cancer cell proliferation and inducing cancer cell apoptosis
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the National Stage of International Application No. PCT/KR2015/013150, filed on Dec. 3, 2015 claiming the priority of KR 10-2014-0175121, filed on Dec. 8, 2014, the content of each of which is incorporated by reference herein.
STATEMENT
Substituted imidazo[1,2-A]pyrazine derivatives as alpha-helix mimetics and method relating to the treatment of cancer stem cells
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
TECHNICAL FIELD
The present invention relates generally to .alpha.-helix mimetic structures and to a chemical library relating thereto. The invention specifically relates to applications in the treatment of cancer and particularly cancer stem cells and pharmaceutical compositions comprising the
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing a cancer comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a second active agent to a patient having a cancer.
2. BACKGROUND
The connection between abnormal protein phosphorylation and the
Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
1. FIELD
Provided herein are methods for treating or preventing a cancer comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of a second active agent to a patient having a cancer.
2. BACKGROUND
The connection between abnormal protein phosphorylation and the
Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
TECHNICAL FIELD OF THE INVENTION
The present invention relates to compounds useful for inhibiting enzymes that maintain and repair the integrity of genetic material. More particularly, the present invention relates to a series of aryl- and heteroaryl-substituted urea compounds, methods of making the
Phenyl-pyridine/pyrazine amides for the treatment of cancer
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
FIELD OF THE INVENTION
The cyclin-dependent kinase (CDK) complexes are well-conserved Ser/Thr kinase family, and it has been shown to be activated by the binding of regulatory partner, generally a cyclin. There are total 20 CDK family members and 5 CDK-like proteins based on the similarities in
Substituted triazolo-pyrazine compounds
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
BACKGROUND OF THE INVENTION
Cancer is the second leading cause of death in the United States, exceeded only by heart disease. (Cancer Facts and Figures 2004, American Cancer Society, Inc.). Despite recent advances in cancer diagnosis and treatment, surgery and radiotherapy may be curative if a
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
Само регистрирани потребители могат да превеждат статии
Вход / Регистрация
FIELD OF THE INVENTION
The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
BACKGROUND OF THE INVENTION
Epigenetic modifications can impact genetic variation but, when dysregulated, can also contribute
Най-пълната база данни за лечебни билки, подкрепена от науката
- Работи на 55 езика
- Билкови лекове, подкрепени от науката
- Разпознаване на билки по изображение
- Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
- Прочетете научни публикации, свързани с вашето търсене
- Търсете лечебни билки по техните ефекти
- Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите
Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания
